They will be able to integrate screening for COPD and asthma exacerbation for those wearable device as well but RAP will need to get class I regulatory approval for this but since ResAppDx does this already and have received class II regulatory approval you would think this won't be an issue, however, the time frame will be quicker than the 6 months submission review needed for ResAppDx.
Ann: Change of Director's Interest Notice - Chris Ntoumenopoulos, page-18
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 89 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)